For MEIP holders.

There results are only a few days away from being released, they could provide a fillip for KZA as well perhaps?

Keep in mind how the US lists dates i.e. 6/3/2019 in our Oz dates that equates to 3/6/2019.

https://finance.yahoo.com/news/mei-pharma-present-clinical-results-210000745.html


Poster Presentations at ASCO 2019
Title: Results of the PI3Kδ inhibitor ME-401 Alone or with Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Date & Time (Poster Display): 6/3/2019, 8:00 -11:00 a.m. CDT
Date & Time (Poster Discussion): 6/3/2019 11:30 a.m. – 1:00 p.m. CDT
Poster Discussion Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract: 7512
Author: Andrew David Zelenetz, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Title: A Randomized Phase 0 Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to the Antiangiogenic (Aa) Bevacizumab in Early HER2-Negative Breast Cancer (E-HERNEBC)
Date & Time: 6/1/2019, 8:00 -11:00 a.m. CDT
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Abstract: 3100
Author: Miguel Quintela-Fandino, M.D., Ph.D., Director of the Clinical Research Program, Centro Nacional De Investigaciones